Skip to main content
Midas Edge

Ensysce Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

ENSC$0.36-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

Preferred Stock · Common Stock · Additional
Number of Shares · Amount · Number of Shares · Amount · Paid-In Capital · Accumulated Deficit · Noncontrolling interests · Total
Balance on March 31, 2025-$-1,644,728$165$134,538,708$(131,489,872)$(328,483)$2,720,518
Issuance of common stock upon exercise of warrants--98,1521142,850--42,861
Issuance of common stock upon warrant inducement, net of issuance cost--630,376632,199,949--2,200,012
Transaction costs associated with warrant inducement----(297,021)--(297,021)
Consultant settlement--20,000236,919--36,921
Stock-based compensation----90,638--90,638
Net loss-----(1,733,351)(166)(1,733,517)
Balance on June 30, 2025-$-2,393,256$241$136,612,043$(133,223,223)$(328,649)$3,060,412
Balance on March 31, 20261,405$-9,277,819$929$142,935,443$(143,276,414)$(328,970)$(669,012)
Issuance of Series B Prefererd Stock2,000---2,000,000--2,000,000
Transaction costs associated with Series B Preferred Stock----(165,295)--(165,295)
Conversions of preferred stock into common stock(2,172)-6,341,085634(634)---
Conversion of 2023 Notes--508,61451246,118--246,169
Settlement of restricted stock units--100,00010(10)---
Consultant compensation----46,310--46,310
Stock-based compensation----1,870--1,870
Net loss-----(2,570,709)(166)(2,570,875)
Balance on June 30, 20261,233$-16,227,518$1,624$145,063,802$(145,847,123)$(329,136)$(1,110,833)
Balance on December 31, 2024-$-1,355,773136$133,252,585$(129,544,299)(328,483)3,379,939
Public offering--239,594251,099,982--1,100,007
Issuance of common stock upon exercise of warrants--147,51315390,840--390,855
Transaction costs associated with public offering----(204,193)--(204,193)
Issuance of common stock upon warrant inducement, net of issuance cost--630,376632,199,949--2,200,012
Transaction costs associated with warrant inducement----(297,021)--(297,021)
Consultant compensation--20,000263,012--63,014
Stock-based compensation----106,889--106,889
Net loss-----(3,678,924)(166)(3,679,090)
Balance on June 30, 2025-$-2,393,256$241$136,612,043$(133,223,223)$(328,649)$3,060,412
Balance on December 31, 20253,305$-4,574,977$459$142,933,260$(139,719,999)$(328,970)$2,884,750
Issuance of Series B Preferred Stock2,000---2,000,000--2,000,000
Transaction costs associated with Series B Preferred Stock----(171,385)--(171,385)
Conversions of preferred stock into common stock(4,072)-11,043,9271,104(1,104)---
Conversion of 2023 Notes--508,61451246,118--246,169
Settlement of restricted stock units--100,00010(10)---
Consultant Compensation--46,31046,310
Stock-based compensation--10,61310,613
Net loss--(6,127,124)(166)(6,127,290)
Balance on June 30, 20261,233$-16,227,518$1,624$145,063,802$(145,847,123)$(329,136)$(1,110,833)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.